IP Library Granted Patent US 10,080,719
Granted Patent B2
US 10,080,719 · App. 15/202,722 · Granted Sep 25, 2018

Allergen dosage form

Inventors: Henrik Hugo Jacobi (Vedbaek, DK); Annette Roemmelmayer Lundegaard (Soborg, DK); Christian Gauguin Houghton (Gentofte, DK); Stig Aasmul-Olsen (Skodsborg, DK); Lise Lund Maerkedahl (Fredensborg, DK); Jan Sondergaard Andersen (Hillerod, DK)
Assignee: ALK-ABELLÓ A/S
A61K9/006A61J1/035A61K9/0056A61K9/19A61K9/2018A61K9/2063A61K9/2095A61K9/7007A61K39/35A61K39/36A61K39/39A61K45/06B65D75/327G01N33/15G01N33/94A61K2039/542A61K2039/545G01N2800/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,080,719
App. No.
15/202,722
Granted
Sep 25, 2018
Kind
B2
Abstract

The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Claims (27)

1. A method for reducing house dust mite-induced allergic symptoms in a patient, said method comprising:

sublingually administering to a patient having at least one clinical allergy symptom of house dust mite-induced allergy a sublingual dosage form containing an effective dose of house dust mite allergen, and

repeatedly administering a sublingual dosage form comprising said effective dose of house dust mite allergen daily to said patient, wherein the method does not comprise an up-dosing phase, wherein the repeated administration of said sublingual dosage forms reduces the at least one clinical allergy symptom, and wherein said allergen is a Dermatophagoides house dust mite allergen.

2. The method of claim 1 , wherein said sublingual dosage form is a tablet.

3. The method of claim 2 , wherein said sublingual tablet is packaged in a multiple tablet blister pack comprising multiple tablets.

4. The method of claim 2 , wherein the sublingual administration comprises placing the tablet under the tongue for at least 1 minute before swallowing.

5. The method of claim 1 , wherein the Dermatophagoides house dust mite allergen comprises Der f 1, Der f 2, Der p 1, and Der p 2.

6. The method of claim 1 , wherein the at least one clinical allergy symptom is reduced in severity or relieved.

7. The method of claim 1 , wherein the at least one clinical allergy symptom is allergic rhinitis.

8. The method of claim 1 , wherein the at least one clinical allergy symptom is asthma.

9. The method of claim 1 , wherein the Dermatophagoides house dust mite allergen is comprised within an extract.

10. The method of claim 9 , wherein the Dermatophagoides house dust mite extract is a freeze-dried extract.

11. The method of claim 9 , wherein the Dermatophagoides house dust mite allergen extract comprises the allergens Der f 1, Der f 2, Der p 1, and Der p 2.

12. A method for treating house dust mite-induced allergy in a patient said method comprising:

sublingually administering to a patient having house dust mite-induced allergy a sublingual dosage form containing an effective dose of house dust mite allergen, and

repeatedly administering a sublingual dosage form comprising said effective dose of house dust mite allergen daily to said patient, wherein the method does not comprise an up-dosing phase, wherein the repeated administration of said sublingual dosage form treats the house dust mite-induced allergy, and wherein said allergen is a Dermatophagoides house dust mite allergen.

13. The method of claim 12 , wherein said sublingual dosage form is a tablet.

14. The method of claim 13 , wherein said sublingual tablet is packaged in a multiple tablet blister pack comprising multiple tablets.

15. The method of claim 13 , wherein the sublingual administration comprises placing the tablet under the tongue for at least 1 minute before swallowing.

16. The method of claim 12 , wherein the Dermatophagoides house dust mite allergen comprises Der f 1, Der f 2, Der p 1, and Der p 2.

17. The method of claim 12 , wherein the house dust mite-induced allergy is reduced in severity or relieved.

18. The method of claim 12 , wherein the house dust mite-induced allergy is allergic rhinitis.

19. The method of claim 12 , wherein the house dust mite-induced allergy is asthma.

20. The method of claim 12 , wherein the Dermatophagoides house dust mite allergen is comprised within an extract.

21. The method of claim 20 , wherein the Dermatophagoides house dust mite extract is a freeze-dried extract.

22. The method of claim 20 , wherein the Dermatophagoides house dust mite allergen extract comprises the allergens Der f 1, Der f 2, Der p 1, and Der p 2.

23. The method of claim 12 , wherein said sublingual dosage form comprises an allergen extract comprising said effective dose of house dust mite allergen.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2018
From: HOUGHTON, CHRISTIAN GAUGUIN; LUNDEGAARD, ANNETTE RÖMMELMAYER; JACOBI, HENRIK HUGO; AASMUL-OLSEN, STIG; MÆRKEDAHL, LISE LUND; ANDERSEN, JAN SØNDERGARD
To: ALK-ABELLÓ A/S
Reel/Frame 045265/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2018
From: MALLINDINE, KERRY; TENG WONG, DESMOND YIK; GARRETT, LISA MARIE; BANBURY, SUSAN GERRARD; HALL, MICHAEL
To: R.P. SCHERER TECHNOLOGIES, INC.
Reel/Frame 045265/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2018
From: MURRAY, OWEN J.
To: R.P. SCHERER TECHNOLOGIES, INC.
Reel/Frame 045265/0378 →
CHANGE OF NAME Recorded Mar 19, 2018
From: R.P. SCHERER TECHNOLOGIES, INC.
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 045630/0114 →
Priority Claims (2)
DK 2002 01825 · Nov 26, 2002 · national
DK 2003 00279 · Feb 24, 2003 · national
Continuity (4)
Continuation 12098150 · Apr 4, 2008
Division 10723308 · Nov 26, 2003
Provisional Application 60429086 · Nov 26, 2002
Related Publication 20160324767A1 · Nov 10, 2016
Cited By (1)
US 12,527,861